Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume After Analyst Upgrade

Shares of Oculis Holding AG (NASDAQ:OCS - Get Free Report) saw strong trading volume on Monday after Chardan Capital raised their price target on the stock from $28.00 to $33.00. Chardan Capital currently has a buy rating on the stock. 41,963 shares changed hands during trading, a decline of 3% from the previous session's volume of 43,324 shares.The stock last traded at $18.90 and had previously closed at $18.70.

OCS has been the subject of several other research reports. HC Wainwright lifted their price target on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Robert W. Baird boosted their price target on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th.

Institutional Trading of Oculis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its holdings in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after purchasing an additional 1,800 shares during the last quarter. Bellevue Group AG bought a new position in shares of Oculis during the 4th quarter valued at $170,000. Bank of America Corp DE lifted its holdings in shares of Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares during the period. Kestra Private Wealth Services LLC bought a new position in shares of Oculis during the 1st quarter valued at $234,000. Finally, XTX Topco Ltd bought a new position in shares of Oculis during the 4th quarter valued at $225,000. Hedge funds and other institutional investors own 22.30% of the company's stock.

Oculis Price Performance

The firm has a fifty day moving average price of $17.96 and a two-hundred day moving average price of $18.40. The stock has a market capitalization of $799.01 million, a P/E ratio of -9.48 and a beta of 0.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). The business had revenue of $0.32 million during the quarter, compared to analysts' expectations of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. As a group, analysts expect that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.